PMID: 12759197May 22, 2003Paper

Principles of drug abuse liability assessment in laboratory animals

Drug and Alcohol Dependence
Nancy A Ator, Roland R Griffiths

Abstract

This paper describes the rationale for use of preclinical assessments of abuse liability in laboratory animals, and then discusses "cross-cutting" methodological issues that apply to behavioral evaluations intended to contribute to an abuse liability evaluation package. Issues include use of: (1) positive and negative control conditions; (2) full dose-effect evaluations, (3) multiple dependent measures, (4) pharmacokinetic evaluations to guide choice of dose ranges, (5) a species for which good methodological and comparative data are available to aid interpretation of results, and (6) appropriate methods for the group or single-subject experimental design selected. The remainder of the paper describes basic methodology by which three core pieces of behavioral data required by the Food and Drug Administration for its use in the overall abuse liability analysis can be obtained preclinically. Reinforcing effects are assessed in study of drug self-administration; drug discrimination assesses degree of overlap of interoceptive stimulus effects with relevant comparison drugs; physical dependence potential is determined by assessing whether a withdrawal syndrome occurs after chronic drug administration. Background and methodological i...Continue Reading

References

Dec 8, 1978·Psychopharmacology·M E Carroll, R A Meisch
May 1, 1979·Clinical Pharmacology and Therapeutics·R R Griffiths, R L Balster
Jan 1, 1978·Annual Review of Pharmacology and Toxicology·R D Spealman, S R Goldberg
Feb 1, 1991·Pharmacology, Biochemistry, and Behavior·D J SpearJ L Katz
Aug 1, 1990·Drug and Alcohol Dependence·G J YutrzenkaW Rosenberger
May 1, 1990·British Journal of Addiction·G Howard
Feb 7, 1989·European Journal of Pharmacology·J H KrystalG R Heninger
Jan 1, 1985·Neuroscience and Biobehavioral Reviews·R R GriffithsJ V Brady
Apr 2, 1985·European Journal of Pharmacology·R J Lamb, R R Griffiths
Mar 1, 1987·Pharmacology, Biochemistry, and Behavior·C E Johanson
Nov 10, 1987·European Journal of Pharmacology·R J Lamb, R R Griffiths
Jul 1, 1988·Journal of the Experimental Analysis of Behavior·R A Meisch, G A Lemaire
Sep 1, 1987·Pharmacology, Biochemistry, and Behavior·K A Grant, C E Johanson
Jan 1, 1985·Psychopharmacology·J Bergman, C E Johanson
Jan 1, 1969·Annual Review of Pharmacology·C R Schuster, T Thompson
Jan 1, 1981·Psychopharmacology·R R GriffithsJ D Snell
Sep 1, 1983·Journal of Pharmacological Methods·W L Woolverton, C R Schuster
Jan 1, 1984·Psychopharmacology·R J CollinsR R Russell
Jan 1, 1983·Psychopharmacology·N A Ator, R R Griffiths
Apr 20, 1984·European Journal of Pharmacology·S E Lukas, R R Griffiths
Jan 1, 1984·Psychopharmacology·S E LukasR M Wurster
Jul 1, 1984·Journal of the Experimental Analysis of Behavior·G A Lemaire, R A Meisch
Dec 1, 1983·Pharmacology, Biochemistry, and Behavior·N A Ator, R R Griffiths
Jan 1, 1983·Progress in Neuro-psychopharmacology & Biological Psychiatry·J H Woods
Jan 1, 1980·Psychopharmacology·S HerlingG D Winger
Oct 1, 1982·Pharmacology, Biochemistry, and Behavior·S E LukasL Daley
Aug 7, 1993·Lancet·R CavallaroE Smeraldi
Dec 1, 1996·Journal of Clinical Psychopharmacology·E Watsky
May 1, 1997·Pharmacopsychiatry·R BottlenderM Soyka
Aug 6, 1999·Psychopharmacology·D C RobertsH Davies

❮ Previous
Next ❯

Citations

Feb 5, 2008·Canadian Journal of Anaesthesia = Journal Canadien D'anesthésie·Ian Gilron
Oct 9, 2007·Psychopharmacology·Mahin ShahbaziKyle J Frantz
Jan 18, 2007·Behavior Genetics·Pamela MettenJohn C Crabbe
Aug 27, 2013·Neuroscience Letters·Eric E Ewan, Thomas J Martin
May 22, 2003·Drug and Alcohol Dependence·Robert L Balster, George E Bigelow
May 22, 2003·Drug and Alcohol Dependence·Roland R GriffithsNancy A Ator
May 22, 2003·Drug and Alcohol Dependence·Kathleen T BradyJoseph V Brady
May 22, 2003·Drug and Alcohol Dependence·Cynthia L Arfken, Theodore J Cicero
May 22, 2003·Drug and Alcohol Dependence·UNKNOWN Expert Panel
Oct 8, 2008·Experimental and Clinical Psychopharmacology·Thomas J Martin, Eric Ewan
Jun 13, 2012·Experimental and Clinical Psychopharmacology·Lisa S MiddletonSharon L Walsh
Aug 16, 2008·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·S Stevens Negus, Kenner C Rice
Oct 22, 2010·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Paul W CzotyMichael A Nader
Apr 22, 2011·Addiction Biology·Rebecca S HoffordShoshana Eitan
Feb 22, 2012·Addiction Biology·Shannon L ColeShoshana Eitan
Oct 1, 2009·The Journal of Pharmacology and Experimental Therapeutics·Nancy A AtorGerard R Dawson
Jul 7, 2011·The Journal of Pharmacology and Experimental Therapeutics·Emily M JutkiewiczJames H Woods
Sep 20, 2007·Nihon yakurigaku zasshi. Folia pharmacologica Japonica·Izuru Miyawaki
May 22, 2008·PloS One·Rixt van der VeenVéronique Deroche-Gamonet
Dec 18, 2012·Advances in Pharmacological Sciences·Matthew L Banks, S Stevens Negus
May 15, 2013·Pharmacology, Biochemistry, and Behavior·Alejandra Aguayo-DelCastilloCésar Casasola
Sep 23, 2010·Behavioural Pharmacology·Amy K Eppolito, Lisa R Gerak
Jul 11, 2013·Behavioural Pharmacology·Lucas R WattersonMichael Foster Olive
Oct 13, 2009·International Clinical Psychopharmacology·Elisabeth FraugerJoëlle Micallef
Apr 16, 2009·International Review of Psychiatry·Ziva D Cooper, Margaret Haney
Nov 6, 2008·Expert Opinion on Drug Safety·Oleg V Tcheremissine
Aug 26, 2009·Pain Medicine : the Official Journal of the American Academy of Pain Medicine·Lynn Webster
May 25, 2012·Drug and Alcohol Dependence·Mehmet Sofuoglu, Mark G LeSage
Sep 28, 2010·Journal of Pharmacological and Toxicological Methods·Paul MoserMark Duxon
May 12, 2010·Drug and Alcohol Dependence·Rebecca S HoffordShoshana Eitan
Jun 29, 2010·Pharmacology, Biochemistry, and Behavior·Eoin C O'Connor, Andy N Mead
Sep 22, 2009·Drug and Alcohol Dependence·Jack E Henningfield, Charles R Schuster

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.